Data / Drug companies / Prasco Laboratories
Prasco Laboratories: 106 products in the FDA NDC directory, labeler code 66993
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Prasco Laboratories (labeler code 66993) lists 106 products in the FDA National Drug Code Directory, covering 43 finished drugs by generic name. By type: 106 prescription drugs. Its main marketing category is authorized generics (NDA). The newest product started marketing on April 6, 2026.
The request: Watch Prasco Laboratories (FDA labeler code 66993): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 66993
- Products in commercial distribution
- 106
- Packages
- 120
- Finished drugs by generic name
- 43
- Prescription products
- 106
- Over the counter products
- 0
- Controlled substance products
- Schedule II 7, Schedule III 5, Schedule IV 4
- Flagged as original packager
- 97 of 97 products that carry the flag
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 14
- Earliest marketing start
- October 1, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Authorized generics (NDA) | 97 | 91.5% |
| Generic drugs (ANDA) | 9 | 8.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 106 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 16 | 15.1% |
| Tablet, coated | 11 | 10.4% |
| Capsule, extended release | 10 | 9.4% |
| Powder | 9 | 8.5% |
| Tablet | 9 | 8.5% |
| Aerosol, metered | 7 | 6.6% |
| Tablet, film coated, extended release | 5 | 4.7% |
| Capsule | 5 | 4.7% |
| Gel | 5 | 4.7% |
| Tablet, chewable | 4 | 3.8% |
| Spray | 3 | 2.8% |
| Solution | 3 | 2.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Umeclidinium Ellipta | 66993-189 | Aerosol, powder | Authorized generics (NDA) | April 6, 2026 |
| Conjugated Estrogens | 66993-299 | Tablet, film coated | Authorized generics (NDA) | February 27, 2026 |
| Conjugated Estrogens | 66993-298 | Tablet, film coated | Authorized generics (NDA) | February 27, 2026 |
| Conjugated Estrogens | 66993-297 | Tablet, film coated | Authorized generics (NDA) | February 27, 2026 |
| Conjugated Estrogens | 66993-296 | Tablet, film coated | Authorized generics (NDA) | February 27, 2026 |
| Conjugated Estrogens | 66993-295 | Tablet, film coated | Authorized generics (NDA) | February 27, 2026 |
| Fluticasone Furoate Ellipta | 66993-168 | Powder | Authorized generics (NDA) | July 21, 2025 |
| Fluticasone Furoate Ellipta | 66993-167 | Powder | Authorized generics (NDA) | July 21, 2025 |
| Fluticasone Furoate Ellipta | 66993-166 | Powder | Authorized generics (NDA) | July 21, 2025 |
| Teriparatide | 66993-989 | Injection, solution | Authorized generics (NDA) | June 16, 2025 |
| Phentermine and topiramate | 66993-783 | Capsule, extended release | Authorized generics (NDA) | June 1, 2025 |
| Phentermine and topiramate | 66993-782 | Capsule, extended release | Authorized generics (NDA) | June 1, 2025 |
| Phentermine and topiramate | 66993-781 | Capsule, extended release | Authorized generics (NDA) | June 1, 2025 |
| Phentermine and topiramate | 66993-780 | Capsule, extended release | Authorized generics (NDA) | June 1, 2025 |
| Testosterone | 66993-955 | Gel | Authorized generics (NDA) | May 19, 2025 |
| Testosterone | 66993-954 | Gel | Authorized generics (NDA) | May 19, 2025 |
| Testosterone | 66993-953 | Gel | Authorized generics (NDA) | May 19, 2025 |
| Testosterone | 66993-952 | Gel | Authorized generics (NDA) | May 19, 2025 |
| Testosterone | 66993-951 | Gel | Authorized generics (NDA) | May 19, 2025 |
| Umeclidinium and Vilanterol Ellipta | 66993-134 | Powder | Authorized generics (NDA) | April 11, 2025 |
| Levetiracetam | 66993-101 | Tablet, for suspension | Authorized generics (NDA) | January 20, 2025 |
| Levetiracetam | 66993-100 | Tablet, for suspension | Authorized generics (NDA) | January 20, 2025 |
| Nitroglycerin | 66993-241 | Spray | Authorized generics (NDA) | December 2, 2024 |
| Dasatinib | 66993-238 | Tablet | Authorized generics (NDA) | September 3, 2024 |
| Dasatinib | 66993-237 | Tablet | Authorized generics (NDA) | September 3, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.